Related Experiment Video
Updated: Nov 18, 2025
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
288
[Immunotherapy for Inflammatory Myopathies].
1Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|February 9, 2021
Summary
Inflammatory myopathies, rare muscle disorders with varied symptoms, lack clear treatment guidelines. Current treatments include corticosteroids and immunoglobulins, with new biologic agents under investigation.
Area of Science:
- Rheumatology
- Neurology
- Immunology
Background:
- Inflammatory myopathies are rare, heterogeneous autoimmune disorders causing muscle inflammation.
- Extra-muscular manifestations are common, affecting skin, lungs, heart, and joints.
- Challenges in diagnosis and treatment arise from low prevalence and varied disease presentation.
Purpose of the Study:
- To review current treatment strategies for inflammatory myopathies.
- To explore the efficacy of established and emerging therapies.
- To highlight the need for evidence-based treatment guidelines.
Main Methods:
- Literature review of current therapeutic approaches.
- Analysis of treatment outcomes for corticosteroids, intravenous immunoglobulins, and immunosuppressive drugs.
- Discussion of ongoing research into biological agents.
Main Results:
- Corticosteroids are the first-line treatment, often based on clinical experience.
- Intravenous immunoglobulins show efficacy as a second-line therapy.
- Biological agents are emerging as a promising area of research with ongoing clinical trials.
Conclusions:
- Treatment for inflammatory myopathies is challenging due to disease heterogeneity and limited trial data.
- A combination of existing therapies and novel biological agents may offer improved outcomes.
- Further research and clinical trials are crucial for developing standardized, effective treatment protocols.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
320
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
320
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
292
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
292
01:20Myasthenia Gravis: Overview and Treatment
2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
299
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
299
01:27Tumor Immunotherapy
860
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
860
01:14Myocarditis III: Medical Management
70
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
70